ORLANDO, FL / ACCESSWIRE / June 20, 2018 / The medicinal cannabis movement is no secret to the public. Elections in states to determine medicinal and recreational use are heavily publicized. Cannabis stocks have been some of the wildest, most heavily played equities in recent memory. All the while an awkward conflict between state and federal law adds to the tension between those who believe in marijuana's medicinal value and those who believe it should still be classified as a Schedule 1 drug alongside the notorious likes of heroin, peyote and LSD. By comparison, cocaine is a Schedule 2 drug in a peer group that contains names like Ritalin and Adderall.
Companies like Cannabis Leaf (OTC PINK: PCFP) Apotheca Biosciences are building a business around the growing sentiment that medicinal cannabis can be a change agent in the war on opiates, developing a business model that is focused on treating the opiate crisis through cannabis-based pain medicines. Recently, the company announced that it has secured the IP rights for Pain Patch, Apotheca Biosciences' pain alleviation technology. This adds a significant asset to Cannabis Leaf's growing portfolio of cannabis-based alternatives and directly aligns with the company's announcement that solving the opioid crisis is its first priority.
As the opiate crisis becomes more recognized and a stated area of focus for this president's administration, leading voices are crying out and reporting on the success of cannabis in addressing the problem.
Take a look:
Marijuana legalization could help offset opioid epidemic, studies find - source: CNN
Key point: "Researchers found that states that allow the use of cannabis for medical purposes had 2.21 million fewer daily doses of opioids prescribed per year under Medicare Part D, compared with those states without medical cannabis laws. Opioid prescriptions under Medicaid also dropped by 5.88% in states with medical cannabis laws compared with states without such laws."
Opioid Use Lower In States That Eased Marijuana Laws - Source: NPR
Key point: "Research suggests that some people turn to marijuana as a way to treat their pain, and by so doing, avoid more dangerous addictive drugs. The findings are the latest to lend support to the idea that some people are willing to substitute marijuana for opioids and other prescription drugs."
Two new studies show how marijuana can help fight the opioid epidemic - Source: Washington Post
Key Point: "There is widespread agreement among doctors and public-health experts that marijuana is effective at treating chronic pain. Doctors often treat that condition with opiate medication, despite little evidence that opiates are effective for it. Marijuana is one of the potential alternative drugs that can provide relief from pain at a relatively lower risk of addiction and virtually no risk of overdose."
For the record, those articles are just from the last few months. And they're not cherry-picked either. Here's the raw Google search. There is far more to support the cannabis claims from established, recognized voices in the media and science than those three news items.
A Pew Research poll from January of this year reported that 61% of Americans approve of legalizing cannabis in general, a number that is likely less than the support for the normally less contentious medicinal purposes.
It is a chorus of supportive voices indeed, present at a collision of a crisis and a potential solution, one where Cannabis Leaf Apotheca Biosciences is aggressively looking to stake its claim and be among the earliest adopters.
For more information on Cannabis Leaf (PCFP) Apotheca Bioscience's products, please visit: www.apothecabiosciences.com/products-pipeline
About Small Cap Sentinel
Emerging Markets Report is owned and operated by Emerging Markets Consulting, a syndicate of investor relations consultants representing years of experience. Our network consists of stock brokers, investment bankers, fund managers, and institutions that actively seek opportunities in the micro and small-cap equity markets.
For more informative reports such as this, please sign up at http://www.emergingmarketsllc.com/newsletter.php
Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described below.
EMC does not, cannot, independently verify any of the claims made by any company included in this release.
EMC has been paid 20,000 by Cannabis Leaf Biosciences for various marketing services including this report. EMC does not independently verify any of the content linked-to from this editorial.
http://emergingmarketsllc.com/disclaimer.php
Emerging Markets Consulting, LLC
Florida Office
15701 State Road 50, Suite #205
Clermont, FL 34711
E-mail: jamespainter@emergingmarketsllc.com
Web: www.emergingmarketsllc.com
SOURCE: Small Cap Sentinel